Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use
Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use
复制标题
DOI：
10.1016/s0140-6736(97)03253-4
复制
发表时间：
1997-11-08
期刊：
影响因子：
168.9
通讯作者：
Levine, OS
中科院分区：
文献类型：
--
作者：
Levine, MM;Levine, OS
新疫苗的开发、实施和持续使用取决于几个因素。尽管疾病负担似乎是确定新疫苗开发和使用优先事项的明显量化指标，但资源并不总是按比例分配。对于发展中国家人民特有的(或在很大程度上有限的)疾病，这一点尤为明显。在决定引进新疫苗时，还需要考虑基于对疾病或疫苗相关风险的看法、新疫苗的成本以及将其纳入现有疫苗接种计划的能力而产生的公众压力。疫苗制造商在新疫苗的开发中发挥着重要作用，因此，必须解决对他们来说重要的问题，即生产、知识产权和产品责任。通过倡导理性决策，在准确信息的支持下，科学家和公共卫生专业人员可以在将新疫苗的潜力转化为新的疫苗可预防疾病的现实方面发挥重要作用。
The development, implementation, and continued use of new vaccines depends on several factors. Although disease burden seems like an obvious quantitative measure for setting priorities for new vaccine development and use, resources are not always allocated proportionately. This is particularly evident for diseases that are unique (or largely limited) to people in developing countries. Public pressure based on perceptions of the risks associated with a disease or vaccine, the cost of new vaccines, and the ability to incorporate them into existing vaccination programmes also need to be considered in the decision to introduce new vaccines. Vaccine manufacturers play an important part in development of new vaccines, and therefore, the issues that are important to them, namely, production, intellectual property rights, and product liability, must be addressed. By advocating rational decisions, supported by accurate information, scientists and public-health professionals can have an important role in transforming the potential of new vaccines into the reality of new vaccine-preventable diseases.